Vericel (VCEL) entered into a 2-year renewable agreement with Orsini Pharmaceutical for distribution of Carticel® and MACI® in the U.S. and Puerto Rico. Orsini will work with Vericel’s service provider, Pro-Spectus, for management of patient cases related to the products.
Concurrently, VCEL announced the pending June 2017 termination of an agreement with Dohmen Life Science Services. As reported with its 2Q16 revenue results, VCEL had entered into collaboration with Dohmen to provide patient support and payor contracting/product reimbursement for Carticel and MACI under a fee-per-service structure.
Sources: Form 8-K for Vericel Corporation, SEC.gov; ORTHOWORLD Inc.
Vericel (VCEL) entered into a 2-year renewable agreement with Orsini Pharmaceutical for distribution of Carticel® and MACI® in the U.S. and Puerto Rico. Orsini will work with Vericel’s service provider, Pro-Spectus, for management of patient cases related to the products.
Concurrently, VCEL announced the pending June 2017 termination of an...
Vericel (VCEL) entered into a 2-year renewable agreement with Orsini Pharmaceutical for distribution of Carticel® and MACI® in the U.S. and Puerto Rico. Orsini will work with Vericel’s service provider, Pro-Spectus, for management of patient cases related to the products.
Concurrently, VCEL announced the pending June 2017 termination of an agreement with Dohmen Life Science Services. As reported with its 2Q16 revenue results, VCEL had entered into collaboration with Dohmen to provide patient support and payor contracting/product reimbursement for Carticel and MACI under a fee-per-service structure.
Sources: Form 8-K for Vericel Corporation, SEC.gov; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
